Icelanders, whose unusually low genetic variability makes them ideal for
studies on the origin of diseases, have agreed to reveal the secrets of their
genes to pharmaceuticals company Hoffmann-La Roche. The deal, worth $200
million, gives the company and its partner—deCode Genetics of
Reykjavik—exclusive rights to develop drugs from the genetic data of
Iceland’s population. In return, Icelanders will receive any resulting medicines
free.
More from New Scientist
Explore the latest news, articles and features
Mind
Why do people ask so few questions in conversation?Â
Comment
Mind
‘Remarkable’ discovery upends our understanding of how brains store memories
News
Humans
DNA reveals a society organised around women in pre-Roman Britain
News
Physics
Quantum entanglement is key to solving 250-year-old maths problem
News
Popular articles
Trending New Scientist articles